Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Circulatory System Panel

This article was originally published in The Gray Sheet

Executive Summary

Cardiac Pathways' premarket approval application for the Chilli cooled ablation system will be reviewed by the advisory panel on July 21 in Gaithersburg, Maryland. The catheter radiofrequency ablation system is designed to treat patients with ventricular tachycardia and is undergoing expedited review ("The Gray Sheet" April 6, In Brief). The potential patient population targeted for treatment with the device is the estimated 160,000 of 400,000 Americans per year who suffer VT or are at risk for the disease. On July 22, the panel will provide FDA with input on clinical trial design for cardiac ablation devices for treatment of atrial fibrillation and atrial flutter. For more information contact FDA's advisory committee information line at 800/741-8138 and use code 12625...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts